SYNTHETIC COMBINATION OF AN HMG COA REDUCTASE INHIBITOR AND A SQUALENE SYNTHETASE INHIBITOR USEFUL IN THE REDUCTION OF THE SERUM CHOLESTEROL MIRROR AND / OR THE PREVENTION OR TREATMENT OF ARTERIOSCLEROSIS

摘要

A pharmaceutical combination is provided which includes an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, such as lovastatin, pravastatin or velostatin, and an inhibitor of the enzyme squalene synthotase. A method for reducing serum cholesterol or inhibiting formation of or treating atherosclerosis using the above combination is also provided.